Yeshiva University Albert Einstein College of Medicine Family Advocacy Pediatric Emergency Medicine
Jacobi Medical Center Resident & Student Area
Lewis M. Fraad Department of Pediatrics (Resident Program)- Albert Einstein College of Medicine - Yeshiva University - Jacobi Medical Center - New York Lewis M. Fraad Department of Pediatrics (Resident Program)- Albert Einstein College of Medicine - Yeshiva University - Jacobi Medical Center - New York
Residency Program Faculty Research and Publications News and Events About the Department Contact Us
Faculty Profile

Back to Faculty listing

Andrew Wiznia, MD
718-918-4664
 andrew.wiznia@nbhn.net

Dr. Wiznia is the Director of the Division of Allergy and Immunology. He is the Director of both the pediatric and adult HIV services at Jacobi. Dr. Wiznia is also the Medical Director of the Division of Research at Jacobi and the co-chair of the New York City HHC Research Committee. Dr. Wiznia has served on numerous state-wide and national HIV committees, and is on the writing committee for the “Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.” Dr. Wiznia is a Professor of Pediatrics at the Albert Einstein College of Medicine.

Undergraduate:
Brandeis University
Medical School:
College of Physicians and Surgeons of Columbia University
Training:
  • Internship and Residency: Bronx Municipal Hospital Center (now Jacobi Medical Center)
  • Chief Residency: Bronx-Lebanon Hospital Center
  • Allergy/Immunology Fellowship: Albert Einstein College of Medicine
Awards and Honors:
  • New York Institute of Technology, Gifts for Special Children Award
  • Pediatric AIDS Foundation, Certificate of Recognition
  • Bronx County Gender Fairness Committee, Com-MEN-dable Person
Research and/or Clinical Interests:
  • Adolescents with HIV
  • Simplifying HAART regimens
  • Interruption of vertical transmission of HIV
  • Surveillance monitoring for antiretroviral treatment
  • HAART
  • Cell mediated immunity in HIV
Bibliography:
  • Saez-Llorens X, Violari A, Ndiweni D, Yogev R, Cashat M, Wiznia A, et al: Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. Pediatrics 2008;121:e827-35
  • Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, et al: CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007;21:2191-9.
  • Wiznia A, Church J, Emmanuel P, et al: Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007;26(9):799-805.
  • Ballan WM, Vu BA, Long BR, Loo CP, Michaëlsson J, Barbour JD, Lanier LL, Wiznia AA, et al: Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol 2007;179:3362-70.
  • Fiscus SA, Kovacs A, Petch LA, Hu C, Wiznia AA, et al: Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). AIDS Res Ther 2007;4:2.
  • Weinberg A, Wiznia AA, Lafleur BJ, Shah S, Levin MJ: Cytomegalovirus-specific cell-mediated immunity in HIV-infected children on HAART. AIDS Res Hum Retroviruses 2006;22:283-8.
  • Abadi J, Sprecher E, Rosenberg MG, Dobroszycki J, Sansary J, Fennelly G, Wiznia A: Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children. J Acquir Immune Defic Syndr 2006;41:298-303.
  • Nozyce ML, Lee SS, Wiznia A, et al: A behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics 2006;117:763-70.
  • Sharp ER, Barbour JD, Karlsson RK, Jordan KA, Sandberg JK, Wiznia A, et al: Higher frequency of HIV-1-specific T cell immune responses in African American children vertically infected with HIV-1. J Infect Dis 2005;192:1772-80
  • King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, et al: Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Pediatr Infect Dis J 2005;24:880-5.
  • Legrand FA, Abadi J, Jordan KA, Davenport MP, Deeks SG, Fennelly GJ, Wiznia AA, et al: Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS 2005;19:1575-85.
  • Rosenblatt HM, Song LY, Nachman SA, Stanley KE, Krogstad PA, Johnson GM, Wiznia AA, et al: Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005;116:698-703.
  • Rosenblatt HM, Stanley KE, Song LY, Johnson GM, Wiznia AA, et al: Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. J Infect Dis 2005;192:445-55.
  • Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM, Krogstad PA, Wiznia AA, et al: Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005;24:352-7.
  • Pelton SI, Stanley K, Yogev R, Fletcher CV, McIntosh K, Wiznia A, et al: Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children. Clin Infect Dis 2005;40:1181-7.
  • Jeremy RJ, Kim S, Nozyce M, Nachman S, McIntosh K, Pelton SI, Yogev R, Wiznia A, et al: Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics 2005;115:380-7.

Copyright © 2004 Lewis M. Fraad Department of Pediatrics. All rights reserved.

Lewis M. Fraad Department of Pediatrics
Albert Einstein College of Medicine at Yeshiva University
1400 Pelham Parkway South
Bronx, New York
10461

www.JacobiPeds.org